What this covers
The episode pairs Jason Kelly, who supplies the biology and synthetic biology background, with Matthew Harrison, who explains how drugs get developed and valued. Jesse is the third voice. Kelly starts with history: the 1978 recombinant insulin, made by cutting and pasting genes with restriction enzymes, and the shift to printing DNA with inkjet technology originally developed at Agilent. He then explains why mRNA, delivered in a lipid nanoparticle, works like a temporary software patch that cells run without altering their DNA.
Harrison's half is about drug economics. He separates technical risk from biological risk and says investors value biotech by discounting each drug's commercial opportunity by its probability of success. The discussion covers how each trial phase raises an asset's value, how clinical testing dominates R&D cost, and why a biomarker shift doesn't prove a target changes the disease. Two claims are flagged as contested: that Technical vs Biological Risk Decomposition leaves mRNA drugs with only biological risk, and that robot-heavy factories, at about $400 million each, and accumulated data form a moat. The speed figures are concrete. A COVID vaccine was designed within days of the viral sequence, and a bench scientist can get a vial for mice in one or two weeks.
On Moderna's own path, the conversation covers the two core technical problems, delivery and chemical modification to evade immune destruction. It also covers the founders' bet on hundreds of drugs rather than one, early partnerships with AstraZeneca and Alexion worth about $300 million upfront, and the later decision to keep full ownership of the COVID vaccine. Kelly adds detours into heme in the Impossible Burger and casein-based dairy alternatives.
Moderna's edge is treating mRNA as a programmable 'software of life' platform, so each new drug reuses the same delivery, manufacturing, and development infrastructure. That makes it a platform company whose later drugs are less risky than one-asset biotech bets.
- Only the mRNA sequence changes between drugs, so technical risk falls after the platform is proven, leaving mainly biological risk.
- Moderna scaled its platform before it had a single lead asset, and funded it at a scale unusual for biotech.
- COVID vaccine revenue, retained 100% ownership, and the fast design cycle show the platform working in practice.
Messenger RNA is executable cell software, so inserting RNA can program cells to make chosen proteins.
- Moderna is the first therapeutics company openly saying it will program patients' cells with DNA or RNA code to make them produce new things, such as a piece of the COVID-19 virus to trigger immunity, and could be extended to many other functions.
“They're the first therapeutics company that's coming right out and saying, 'What we're going to do is program your cells with DNA, or RNA in their case, code.'”
- The mRNA vaccine works by delivering messenger RNA inside a lipid nanoparticle into cells, where ribosomes read it and make a viral protein, which the immune system recognizes and learns to fight, so the vaccine programs the body to make a harmless piece of the virus.
“your cell is going to read that mRNA... The ribosome is going to read it, and they're going to make a little piece of the virus. And then your cell is going to essentially express that and show it to the immune system.”
- Messenger RNA is the software a cell is currently executing, since cells choose which DNA genes to turn into RNA depending on conditions, and Moderna's idea is to insert RNA for a chosen disease and let the cell run it, which could be done for COVID, cancer, or heart disease.
“What I would say is the mRNA is the software your cell is currently executing... tomorrow it could be RNA for cancer treatment, or heart disease, or whatever.”
- Messenger RNA is the code a cell is actively executing, while DNA is the stored genome, so injecting mRNA is like a temporary software patch that cells run without it altering the underlying DNA.
“the mRNA is the software your cell is currently executing”
The COVID mRNA vaccine marks a turning point, opening a third drug category after small molecules and proteins.
- Jason argues that the Moderna and BioNTech RNA vaccines, with about 95% efficacy, mark a turning point comparable to Genentech's insulin in 1978, opening a new drug category based on nucleic acids.
“To me, that is Genentech and insulin all over again, but for a whole new category of drugs.”
- The Moderna COVID-19 vaccine is the first RNA vaccine ever approved and the largest rollout of any nucleic acid drug in history.
“It is the first ever RNA vaccine.”
- Nucleic acid drugs are the third wave in pharma after small molecules and protein drugs, and investors should move quickly into this area because it may produce successors to insulin.
“To me it's like, this is the third wave in the pharma industry, pay attention... I think they're going to be the next insulins and everything else.”
- The COVID vaccine established that RNA drugs work, opening the third era of therapeutics after small molecules and proteins, so that one more successful drug would make Moderna the obvious next Genentech.
“the COVID-19 vaccine has established that works. That opens the door and all they got to do is do one more drug.”
- Moderna's head start in RNA drugs gives it an advantage in pursuing the low-hanging fruit of this modality, though many competitors will follow.
“They can get drugs out right now, and we believe that this they're called modality... they're ahead of other people and pursuing all the other low-hanging fruit for that.”
- Even with fast mRNA design, clinical trial duration is the longest step in drug development, so faster design does not compress total timelines as much as the headline speed suggests.
“the longest time period of this whole thing was running the clinical trial.”
- Without mRNA synthesis and the programmable platform, the COVID vaccine's timeline (design shortly after sequencing, testing, and first human dosing within about a year) would have taken far longer, with the clinical trial being the longest step.
“Keep in mind the longest time period of this whole thing was running the clinical trial.”
DNA is digital code that can be read and written, so cells can be engineered like computers.
- First-generation genetic engineering was like cut and paste: scientists could only move genes that existed in nature. Synthetic biology, by contrast, lets scientists design DNA as they want through DNA printing, removing that limit.
“You're actually able to design that DNA however you want because you're using DNA printing to make it. And so you aren't any more limited by just what you can cut and paste.”
- Every cell contains digital code in DNA made of A, T, C, and G. Unlike computer bits, this code can be read by sequencing and written by printing it in a lab, so cells can in principle be programmed.
“inside every cell is digital code in the form of DNA... you can read this code... And then importantly, you can also write DNA.”
- Biology stores heritable information digitally in A, T, C, and G, which allows high-fidelity copying across generations, the same principle that makes CDs and digital files copy perfectly, but implemented in chemicals rather than magnetic bits.
“Biology figured out the exact same thing... digital. A, T, Cs, and Gs. It just happens to do it, not with magnetic bits on a computer, but with actual chemicals.”
- DNA is now printed using inkjet technology, originally developed at Agilent, a Hewlett-Packard division, that spots A, T, C, and G onto a slide in roughly 100-letter pieces, which are then stitched into 1,000 to 10,000-letter gene-length sequences.
“they took inkjet printing technology instead of ink in there, they put the A, T, Cs, and Gs and they spotted on a little slide.”
- All cells in the body share the same genome, and differences such as eye versus nose cells come from which genes are switched on, so cells can run different programs from one underlying code.
“the same genome makes your eyes cells as your nose, and it's just, what genes are getting turned on, allows you to run different programs”
A platform model sharing cell-programming technology across applications creates an ecosystem that improves over time.
- Moderna pitched itself as a platform for sending RNA into cells, not a single drug company, and used that to sign early deals with AstraZeneca and Alexion totaling about $300 million upfront, while keeping the rest of the platform for itself.
“they did the deal with AstraZeneca, it was just in one area, but they reserved all the rest of their platform for themselves... those two deals together were like $300 million in upfront.”
- Horizontal platform companies like Ginkgo supply the underlying cell-programming technology, and vertical application companies like Moderna, and the food and materials startups built on top of them, improve that platform as they scale, creating an ecosystem similar to cloud platforms.
“these horizontal platform companies like Ginkgo are benefiting, and then we turn around and enable new app companies in other markets.”
- Entrepreneurs in fields like building materials can use synthetic biology without being biotech experts by contracting platform companies like Ginkgo, similar to how Amazon Web Services let founders launch websites without server expertise.
“You could be a building materials, you don't need to be a biotech expert, you can call a company like Ginkgo and get the biotech done.”
- Moderna's therapeutics success drives down the cost and improves the tools of the underlying synthetic biology platform, which in turn benefits downstream application companies such as those in food, like better vegan cheese within a year.
“they are one of the great apps that's driving improvements in the OS.”
- Kelly compares Moderna and Ginkgo to a database technology that many companies later use, arguing that horizontal platforms are reused across applications, which is the same dynamic he sees in synthetic biology.
“That's exactly the same idea. So these horizontal platform companies like Ginkgo are benefiting, and then we turn around and enable new app companies in other markets.”
Early leaders gain compounding infrastructure and data advantages that make their platforms hard for competitors to replicate.
- Biotech advantage compounds through physical infrastructure, such as robot-heavy factories costing about $400 million, and data assets, because each run teaches the company how to do the next one better, creating a moat hard for competitors to replicate.
“every time we do something, we learn how to do it better... Google has 25 years of search data to train their algorithms and you don't.”
- Standard drug development is one-off because a startup that succeeds with one drug gains little advantage for the next, while a platform that uses the same cell-code mechanism means later drugs become more likely to work.
“drugs are pretty much all one-offs. Just because one startup company makes a drug, they won't have any better shot at making the next one.”
- Jason says Ginkgo treats culture as central, emphasizing a scientifically careful workplace, but he argues that compounding technological heft from infrastructure and data is the irreplaceable advantage.
“I think culture is really important, we're really careful about our culture at Ginkgo... The things that give you the compounding advantage over time... is just irreplaceable.”
- Early leaders in a therapy modality accumulate compounding advantages as each successful drug adds data and know-how, making it hard for competitors to catch up, as Genentech and Biogen did with protein drugs.
“There's compounding of the learning and of all the things that are just hard to catch up with effectively”
- Google's search advantage comes from roughly 25 years of accumulated search data used to train its algorithms, and similar data compounding is the central competitive asset in synthetic biology, where whoever has the most data wins.
“Google has 25 years of search data to train their algorithms and you don't.”
Synthetic biology will disrupt physical-goods industries such as food, materials, and medicine by replacing animal and chemical inputs.
- Computers are programmable but only move information, while cells are programmable and move atoms, so synthetic biology will disrupt physical-goods industries such as food, medicine, building materials, and electronics.
“it doesn't move bits around, it moves atoms. So if you think of what's going to get disrupted in the era of synthetic biology, it's all the physical goods industries.”
- The Impossible Burger's bleeding effect comes from heme, made by inserting the hemoglobin gene into brewer's yeast, so programmed cells supply key taste and smell components in plant-based meat.
“they found the gene for hemoglobin... and they moved it into, in this case, the brewer's yeast... instead of beer coming out, heme comes out.”
- Vegan cheese is poor because plants have no protein that replicates casein, the milk protein that makes cheese stretch, and synthetic biology can now produce casein without animals, enabling better dairy-free cheese and ice cream with environmental and animal welfare benefits.
“There's no replacement for it. There's nothing in plants that does it.”
- Biotech can produce carbon-neutral building materials that corporate buyers want, creating a major opportunity for companies outside biotech.
“There's big opportunity in using biotech to make carbon-neutral building materials.”
- Biology is the world's best recycling system, and companies such as Allonia are using engineered biology to break down hard-to-degrade pollutants like PFAS.
“Well, the other thing that biology does in addition to making all kinds of stuff is it's the world's best recycling system.”
- Companies are making leather bags without cows and working on fire remediation, reflecting synthetic biology's replacement of animal-derived materials across industries.
“A number of companies working on leather bags without the cow, as another example, where you're seeing it replaced.”
Cheaper DNA writing and laboratory automation have vastly expanded how many biological designs can be tested.
- PCR, invented in the late 1970s, lets scientists select a region of DNA and make billions of copies by hijacking cells' natural replication machinery, so that enough material exists to work with in the lab.
“what PCR lets you do is basically pick a certain region of DNA and make a billion copies of it.”
- Writing DNA has become much cheaper and higher-throughput, and the scale of lab work has grown enormously: Jason did about 50,000 DNA letters over five years in grad school, while Ginkgo now does about 50 million letters in a month.
“in grad school, I probably did 50,000 letters of DNA in 5 years at MIT, a big month at Ginkgo today will be like 50 million letters.”
- In early biotech, work was so laborious that if a design failed in the first 10 or 50 attempts, it was unlikely to ever succeed, because researchers could not try enough designs.
“If you didn't get it to work in the first 10 or 50, you were never going to get it to work because you just couldn't try that many designs.”
- Lab work moved from manual pipetting, where a grad student might test only one gene design at a time with very few attempts, to robotic automation and data analytics that can run 10,000 to 20,000 experiments, changing the capacity of biological research.
“where they could do one gene, we can do 10 or 20,000. It's a really big change in capacity.”
- Progress in biology since the late 1970s has been driven mainly by computing, laboratory robotics, and better bench tools such as CRISPR, rather than by any single scientific breakthrough.
“Computing and laboratory robotics and then continued innovation in the tools at the bench”
Drug value rises with each passed trial phase, and partnership deal structures shape who captures that value.
- A typical drug progresses from an academic lab idea into phase one safety trials, then phase two efficacy trials in a patient group, then phase three larger trials, and big pharma companies often buy assets at any stage based on early results.
“they'll put it into like a phase one clinical trial... And then phase three is like in a lot of people.”
- Once Moderna reached critical mass, it kept rights to its own drugs, so it could fund trials and own 100% of the upside on its COVID-19 vaccine without a partner, in contrast to earlier partnership-based deals.
“I'm actually going to launch my own drugs in the future that I own 100% of. And that's like the COVID-19 vaccine. That's not partnered with anybody.”
- The FDA acts as a third-party arbiter of efficacy, so each passed trial phase sharply increases a drug's commercial value, with Jason's estimates rising from about $50 million to $500 million to a far larger figure after phases one, two, and three.
“the FDA is the arbiter of efficacy. And that's why those points are so value at creative at each phase.”
- BioNTech, the partner of Pfizer, was too small to develop its RNA vaccine alone because it lacked the resources to run a large clinical trial, even though it had a lucky breakthrough.
“BioNTech was just too small to do it on their own. They had lightning in a bottle obviously.”
- Pharma deals typically pair a large upfront payment for exclusive rights with milestone payments called biobucks, which pay out royalties or lump sums if the drug reaches later clinical stages or commercial success.
“in industry it will be called bio bucks”
Genetic engineering history began with restriction enzymes and insulin, and CRISPR refines that same bacterial tool.
- Biotech historically meant developing therapeutics through genetic engineering, starting in the late 1980s when a gene from one species could be moved into another, with the first product being human insulin made in E. coli grown in large tanks.
“Take the gene for human insulin, which diabetics can't make... put it into a bacteria like an E. coli or something, grow it up in a big tank and it makes human insulin.”
- The first recombinant insulin in 1978 used restriction enzymes, bacterial molecular scissors evolved to chop up foreign viral DNA, to cut both the bacterial genome and the PCR-amplified insulin gene so the ends matched and could be pasted together.
“A technology called restriction enzymes, which are basically scissors... I'm going to use the scissor to cut the bacterial genome and the PCR products so that they match each other, and then I just paste them together.”
- CRISPR is the modern, more precise form of restriction enzymes, both descended from a bacterial defense that cuts up incoming foreign DNA, and it gives scientists a better gene-editing tool than the 1978 scissors.
“the more modern form of these restriction enzymes is what's called CRISPR.”
- The first wave of protein drugs had a small set of obvious targets, such as diabetics missing insulin and children missing human growth hormone, so early leaders such as Genentech and Biogen captured them first.
“Why did Genentech gets so big? Why did Biogen gets so big? Because they were right there on the first day... There was like a very obvious set of 5 or 6 diseases.”